Success Metrics

Clinical Success Rate
84.6%

Based on 11 completed trials

Completion Rate
85%(11/13)
Active Trials
1(6%)
Results Posted
55%(6 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_4
3
19%
Ph phase_2
3
19%
Ph phase_3
5
31%
Ph not_applicable
1
6%
Ph phase_1
2
13%

Phase Distribution

2

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
3(21.4%)
Phase 3Large-scale testing
5(35.7%)
Phase 4Post-market surveillance
3(21.4%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

1

trials recruiting

Total Trials

16

all time

Status Distribution
Active(1)
Completed(11)
Terminated(2)
Other(2)

Detailed Status

Completed11
Terminated2
unknown2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
1
Success Rate
84.6%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 23 (21.4%)
Phase 35 (35.7%)
Phase 43 (21.4%)
N/A1 (7.1%)

Trials by Status

active_not_recruiting16%
completed1169%
terminated213%
unknown213%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT06397768Phase 3

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Terminated
NCT05794230Phase 3

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Completed
NCT06647407Phase 1

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Active Not Recruiting
NCT03673462Phase 3

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Completed
NCT01049035Phase 2

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Completed
NCT05212935

A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy

Unknown
NCT02482636Phase 2

Baby Vaccine Study (Sched3)

Completed
NCT04123119Not Applicable

Development of a Live Attenuated Rotavirus Vaccine as a Human Infection Challenge Model

Completed
NCT01480258Phase 3

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Completed
NCT01616693Phase 4

Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines

Completed
NCT00140686Phase 3

To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines

Completed
NCT00346892Phase 2

To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV

Completed
NCT01195844

Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).

Terminated
NCT02153866Phase 4

The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine

Unknown
NCT01199874Phase 4

Immunogenicity of Rotavirus Vaccine

Completed
NCT00981669Phase 1

Rotavirus Vaccine Produced by Butantan Institute

Completed

All 16 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
16